Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Titel:
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
Auteur:
Huppert, L.A. Wolf, D. Yau, C. Brown-Swigart, L. Hirst, G.L. Isaacs, C. Pusztai, L. Pohlmann, P.R. DeMichele, A. Shatsky, R. Yee, D. Thomas, A. Nanda, R. Perlmutter, J. Heditsian, D. Hylton, N. Symmans, F. van’t Veer, L.J. Esserman, L. Rugo, H.S.